- Home
- PDCC vs BDSX Comparison
PDCC vs BDSX Comparison
Compare PDCC & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDCC
- BDSX
- Stock Information
- Founded
- PDCC N/A
- BDSX 2005
- Country
- PDCC
- BDSX United States
- Employees
- PDCC N/A
- BDSX N/A
- Industry
- PDCC
- BDSX Precision Instruments
- Sector
- PDCC
- BDSX Health Care
- Exchange
- PDCC NYSE
- BDSX Nasdaq
- Market Cap
- PDCC 136.9M
- BDSX 115.4M
- IPO Year
- PDCC N/A
- BDSX 2020
- Fundamental
- Price
- PDCC $17.81
- BDSX $0.37
- Analyst Decision
- PDCC
- BDSX Strong Buy
- Analyst Count
- PDCC 0
- BDSX 4
- Target Price
- PDCC N/A
- BDSX $2.83
- AVG Volume (30 Days)
- PDCC N/A
- BDSX 575.4K
- Earning Date
- PDCC N/A
- BDSX 05-13-2025
- Dividend Yield
- PDCC N/A
- BDSX N/A
- EPS Growth
- PDCC N/A
- BDSX N/A
- EPS
- PDCC N/A
- BDSX N/A
- Revenue
- PDCC N/A
- BDSX $71,323,000.00
- Revenue This Year
- PDCC N/A
- BDSX $32.90
- Revenue Next Year
- PDCC N/A
- BDSX $24.65
- P/E Ratio
- PDCC N/A
- BDSX N/A
- Revenue Growth
- PDCC N/A
- BDSX 45.30
- 52 Week Low
- PDCC N/A
- BDSX $0.45
- 52 Week High
- PDCC N/A
- BDSX $2.04
- Technical
- Relative Strength Index (RSI)
- PDCC N/A
- BDSX 29.45
- Support Level
- PDCC N/A
- BDSX $0.34
- Resistance Level
- PDCC N/A
- BDSX $0.58
- Average True Range (ATR)
- PDCC 0.00
- BDSX 0.06
- MACD
- PDCC 0.00
- BDSX -0.01
- Stochastic Oscillator
- PDCC 0.00
- BDSX 12.15
About PDCC PEARL DIVER CREDIT COMPANY INC
PEARL DIVER CREDIT COMPANY INC is a non-diversified closed ended management investment company.
About BDSX Biodesix Inc.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.